Citadel Advisors’s Interpace Biosciences, Inc. Common Stock IDXG Stock Holding History

Citadel Advisors’s Portfolio IDXG Stock Details IDXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-11,858	Closed	-$37K	–	11920
2020 Q3	$37K	Buy	+11,858	New	+$53.7K	﹤0.01%	9704
2019 Q2	–	Sell	-3,262	Closed	-$26K	–	10239
2019 Q1	$26K	Buy	+3,262	New	+$30.7K	﹤0.01%	9019
2018 Q3	–	Sell	-2,618	Closed	-$23K	–	9965
2018 Q2	$23K	Buy	+2,618	New	+$23.2K	﹤0.01%	8617
2018 Q1	–	Sell	-1,928	Closed	-$20K	–	9057
2017 Q4	$20K	Buy	1,928 +43	+2%	+$520	﹤0.01%	7833
2017 Q3	$29K	Buy	+1,885	New	+$22.3K	﹤0.01%	7295
2016 Q4	–	Sell	-1,086	Closed	-$17K	–	8144
2016 Q3	$17K	Buy	1,086 +603	+125%	+$16.7K	﹤0.01%	7099
2016 Q2	$16K	Buy	+483	New	+$18.2K	﹤0.01%	6681
2013 Q3	–	Sell	-144	Closed	-$68K	–	6951
2013 Q2	$68K	Buy	+144	New	+$65.3K	﹤0.01%	5485

Other funds holding IDXG

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Allworth Financial Folsom, California $23.6B AUM 20.99% 1-Year Est. Return

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return

Citadel Advisors's IDXG Position: Q4 2020 in Review

Citadel Advisors sold out of Interpace Biosciences, Inc. Common Stock (IDXG) in Q4 2020, closing a stake of 11,858 shares — an estimated $37K sold.

Citadel Advisors first reported a position in IDXG in Q2 2013 and held it in 8 quarters. The position peaked at $68K in Q2 2013. 12 funds tracked by Wall St. Rank hold IDXG as of Q4 2020.

Citadel Advisors reported no remaining Interpace Biosciences, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
Citadel Advisors sold 11,858 Interpace Biosciences, Inc. Common Stock shares in Q4 2020, an estimated $37K.
Citadel Advisors first reported a position in Interpace Biosciences, Inc. Common Stock in Q2 2013 and held it in 8 quarters.
Citadel Advisors's Interpace Biosciences, Inc. Common Stock position peaked at $68K in Q2 2013.
12 funds tracked by Wall St. Rank held Interpace Biosciences, Inc. Common Stock as of Q4 2020.

Based on Citadel Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.